The process of treating HIV patients in Africa has improved markedly due to cooperation between pharmaceutical companies, which has led to increasing access to higher quality medicines.

Without profound changes in the scientific and regulatory environment, things will remain very tough for the agile disruptor -- relatively good news for established giants, presumably less good news for patients and for progress.

The crisis in financing is having a chilling effect on biomedical innovation. As discussed in my last column, the main problem in our industry is that the sheer cost of drug development has become almost prohibitively expensive, effectively pricing almost everyone but the largest companies out of the market.

It’s easy to muster a cynical response to Tuesday’s announcement that the world’s largest health products company, J&J, is replacing their current CEO William Weldon (athletic white male and former sales rep who rose through the commercial organization) with Alex Gorsky (athletic ...

US/EU companies that protect their drug brands in turn protect our lives. We need other countries to do more and we need to help them in doing so.

India is on the brink of finalizing a free trade agreement with the European Union. Yet even as the deal gets close, one area remains hotly contested: protection for intellectual property (IP). Controversy mounts over "data exclusivity" for pharmaceuticals.

Some activist groups' rhetoric hurts the search for an AIDS cure.

Ensuring that there are profits to be made from HIV/AIDS is probably the best way to keep companies investing and researching.